Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

16.58 -0.57 (-3.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,585,481
Open 17.32
Bid (Size) 16.50 (1)
Ask (Size) 16.79 (10)
Prev. Close 17.15
Today's Range 16.41 - 17.80
52wk Range 4.980 - 19.95
Shares Outstanding 151,373,044
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top 5 Best And Worst U.S. Industry ETFs In Q1 2023: AI and Bank Turmoil Shaped Stock Returns
The first quarter of 2023 was positive for the U.S. stock market as a whole, with the S&P 500 index faithfully tracked by the SPDR S&P 500 ETF Trust (ARCA: SPY), rising by 6%. 
Via Benzinga
Stocks Rise As Investors Bet On Bank Recovery
Stocks are swinging higher today, as bond yields retreat and Wall Street bets that the worst of the regional banking crisis is in the rearview mirror. 
Via Talk Markets

Performance

YTD
+131.24%
+131.24%
1 Month
+46.86%
+46.86%
3 Month
+117.59%
+117.59%
6 Month
+66.80%
+66.80%
1 Year
+63.35%
+63.35%

More News

Read More
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
Via Benzinga
4 Analysts Have This to Say About BridgeBio Pharma
Via Benzinga
Rare Disease Player BridgeBio Pharma Draws Attention Of Big Pharma Companies, Gets Takeover Interest
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via Globe NewsWire
BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope
Via MarketBeat
Topics Economy
Exposures Interest Rates
Why BridgeBio Pharma Shares Are Falling Sharply
Via Benzinga
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
Via Benzinga
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via Globe NewsWire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Tesla, Amazon, Ambrx, BridgeBio, Azul: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via Globe NewsWire
Why BioMarin Shares Are Plunging Today?
Via Benzinga
These 2 Biotech Stocks Made Big Monday Moves
Via The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
Via Benzinga
Why BridgeBio Pharma Stock Is Skyrocketing Today
Via The Motley Fool
Stocks Rise As Bond Yields Fall; Investors Await Economic Data
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.